Volume 7, Issue 2 (12-2020)                   vacres 2020, 7(2): 97-100 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Maestroni G. The Well-Recognized Ability of Melatonin to Potentiate an Equilibrated Immune Response Calls for an Urgent Study about Its Use as an Adjuvant in Anti-SARS-CoV-2 Vaccines. vacres. 2020; 7 (2) :97-100
URL: http://vacres.pasteur.ac.ir/article-1-258-en.html
Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy
Abstract:   (264 Views)
Vaccines are a major weapon to control the present COVID-19 pandemic. To achieve this goal, vaccines should confer a robust and long-lasting immunity against SARS-Cov-2. Breakthrough infections and waning immunity are currently observed in patients that recovered from COVID-19 as well as in the vaccinated people. Therefore, a highly effective vaccine is needed to control the present and future outbreaks. Exogenous N-acetyl-5-methoxy-tryptamine or melatonin (MLT) is well known to potentiate an effective and equilibrated immune response in a variety of situation including viral and bacterial infections and vaccines against different microbial and cancer antigens. In regard to anti-SARS-Cov-2 vaccines, beside stimulating specific IgG production as well as specific CD4+ and CD8+ T cells, exogenous MLT might also enhance specific IgA and secretory IgA in the mucosae; hence, preventing the re-infection and/or asymptomatic transmission of the virus. Thus, a study is urgently proposed to evaluate the effects of MLT administration either before or after vaccination against SARS-Cov-2 to evaluate its effect on strength, quality and duration of the immunity. Las but not least, due to its powerful antioxidant and anti-inflammatory properties, MLT administration might minimize the occurrence of adverse events after the vaccination.
Full-Text [PDF 238 kb]   (97 Downloads)    
Type of Study: Short communication | Subject: Humanand veterinary vaccines
Received: 2021/08/21 | Accepted: 2020/12/1 | Published: 2021/09/26

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.